Free Trial
NASDAQ:ABSI

Absci Q4 2023 Earnings Report

Absci logo
$2.66 0.00 (0.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$2.64 -0.02 (-0.56%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Absci EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Absci Revenue Results

Actual Revenue
$0.34 million
Expected Revenue
$1.75 million
Beat/Miss
Missed by -$1.41 million
YoY Revenue Growth
N/A

Absci Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 21, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Absci's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Absci Earnings Headlines

Analysts Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40
Absci (NASDAQ:ABSI) Upgraded at Wall Street Zen
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
HC Wainwright Analysts Raise Earnings Estimates for Absci
See More Absci Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Absci? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Absci and other key companies, straight to your email.

About Absci

Absci (NASDAQ:ABSI) operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

View Absci Profile

More Earnings Resources from MarketBeat